We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





AstraZeneca-Oxford COVID-19 Experimental Vaccine Triggers Similar Protective Antibodies and T-Cells in Both Older and Younger Adults

By HospiMedica International staff writers
Posted on 27 Oct 2020
Print article
Image: AstraZeneca-Oxford COVID-19 Experimental Vaccine Triggers Similar Protective Antibodies and T-Cells in Both Older and Younger Adults (Photo courtesy of AstraZeneca)
Image: AstraZeneca-Oxford COVID-19 Experimental Vaccine Triggers Similar Protective Antibodies and T-Cells in Both Older and Younger Adults (Photo courtesy of AstraZeneca)
Early trial results of AstraZeneca Plc’s (Cambridgeshire, England) COVID-19 vaccine candidate suggest that the group most vulnerable to serious illness and death could build immunity as the vaccine has been found to trigger protective antibodies and T-cells in older age groups.

AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). According to a report by The Financial Times, the AstraZeneca-Oxford COVID-19 experimental vaccine triggered protective antibodies and T-cells in older age groups, providing much encouragement to researchers who have been searching for proof of the vaccine’s ability to protect these groups from serious illness or death from the SARS-Cov-2 virus.

Age is now considered as the primary risk factor for COVID-19 severity as the immune system weakens with age. This has raised concerns that a COVID-19 vaccine may fail to protect the very group that generates the least effective response to the SARS-Cov-2 virus. However, early results from immunogenicity blood tests performed on a subset of older participants from trials of the AstraZeneca-Oxford COVID-19 experimental vaccine have shown that the vaccine also triggered protective antibodies and T-cells in older age groups. These results match data released in July that showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55 years, according to The Financial Times. The earlier data had shown that the vaccine induced both antibodies as well as T-cells for at least 56 days.

Researchers are encouraged by the latest development, although positive immunogenicity tests do not guarantee that a COVID-19 vaccine is safe and effective for older people which can be confirmed only after full trial data for the age group has been analyzed.

Related Links:
AstraZeneca
University of Oxford


Gold Member
12-Channel ECG
CM1200B
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
Hospital Data Analytics Software
OR Companion
New
Ultrasonic Cleaner
Cole-Parmer Ultrasonic Cleaner with Digital Timer

Print article

Channels

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.